CLX
53
-2
SRCL
48
-2
KMX
49
2
DGX
58
8
KSS
37
4
AEE
43
-2
SBUX
50
-2
ZION
55
3
T
38
2
WDC
55
2
HBI
30
12
AN
54
4
STI
9
8
HST
55
5
LYB
39
2
FOX
39
2
DIS
72
3
VLO
38
5
HOG
43
3
DNB
24
2
CLX
53
-2
SRCL
48
-2
KMX
49
2
DGX
58
8
KSS
37
4
AEE
43
-2
SBUX
50
-2
ZION
55
3
T
38
2
WDC
55
2
HBI
30
12
AN
54
4
STI
9
8
HST
55
5
LYB
39
2
FOX
39
2
DIS
72
3
VLO
38
5
HOG
43
3
DNB
24
2
Financhill
Back

Phathom Pharmaceuticals 10K Form

Buy
62

PHAT
Phathom Pharmaceuticals

Last Price:
9.11
Seasonality Move:
1.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PHAT News And Ratings

See the #1 stock for the next 7 days that we like better than PHAT

PHAT Financial Statistics

Sales & Book Value

Annual Sales: $682K
Cash Flow: $-44.27M
Price / Cash Flow: 0
Annual Sales: $-1.26
Price / Book: 0

Profitability

EPS (TTM): -3.94000
Net Income (TTM): $-201.59M
Gross Margin: $515K
Return on Equity: 0%
Return on Assets: 0%

Phathom Pharmaceuticals Earnings Forecast

Key Phathom Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 2 years for PHAT is 75.51%.
  • The Selling, General & Administrative Expenses for PHAT have been equal to 17,291.50% of Gross Profit Margin.
  • The Research & Development expenses have been 7,316.57% of Revenue.
  • The Interest Expense is -20.82% of Operating Income.
  • The Net Earning history of PHAT is -29,558.94% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Phathom Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PHAT
CUSIP: 71722W
Website: phathompharma.com

Debt

Debt-to-Equity Ratio: -1.89
Current Ratio: 10.25
Quick Ratio: 9.88

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PHAT Technical Analysis vs Fundamental Analysis

Buy
62
Phathom Pharmaceuticals (PHAT) is a Buy

Is Phathom Pharmaceuticals a Buy or a Sell?